Standardized difference (STD) was used to assess differences between the GLP-1 RAs and basal insulin group, with values of 50% eGFR decline, ESKD, or all-cause mortality, compared to either initiators of DPP4 inhibitors or sulfonylureas [28]
How Genetic Predispositions Add Clinical Context Emerging evidence suggests genetic variation in GLP-1 and related metabolic pathways influences how individuals respond to treatment
But it also helps to understand your options
Understanding Glucagon-Like Peptides: The Basics Before diving into the differences, lets establish what glucagon-like peptides are and where they come from
Myth GLP-1 medications are a quick fix Myth Everyone loses weight in the same way Myth GLP-1 medications simply "turn off hunger" Myth Online programs offer the same care as medical clinics
Traditionally, Wegovy has been prescribed as a weekly injection